Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update • Q1 2024 YUPELRI (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 • Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvement • Continued progress for ampreloxetine CYPRESS enrollment • Virtual ampreloxetine KOL event scheduled for May 23, 2024 • Q1 2024 ending cash balance of $100 million DUBLIN, IRELA ...